Drugs and patents involved
The Ranbaxy-Pfizer dispute involves three drugs:Lipitor, Caduet and Norvasc. The last named is a blood pressure drug. Pfizer's patent over it was annulled recently ending a lucrative monopoly: Norvasc, Pfizer's second biggest selling drug, earned the company about US$5 billion in sales in 2006. But the company combined one of its key ingredients with a constituent of the second drug in the picture: Lipitor
Related Content
- Order of the High Court of Delhi regarding supply and availability of the drug Tocilizumab 400 MG for COVID-19 patients, 10/05/2021
- The political origins of health inequity: prospects for change
- Novartis plea for patent of cancer drug: Supreme Court verdict today
- Bring order to unregulated health markets
- Patent office strips Roche of rights over Valcyte
- Innovation and technology transfer to address climate change